TiGenix : manufacturing license obtained for European production facility
(Thomson Reuters ONE) -
Regulated information
april 24, 2012
TiGenix obtains manufacturing license for European production facility
Leuven (BELGIUM) - April 24, 2012 - TiGenix (NYSE Euronext: TIG) announced today
that further to the cGMP inspection by the Dutch authorities it has obtained the
manufacturing authorization for human medicinal products for its European
manufacturing plant in Sittard-Geleen in the Netherlands.
"I'd like to commend our manufacturing team responsible for building and
validating our production plant in record time and passing the inspection of the
Dutch regulatory authorities with flying colors," said Eduardo Bravo, CEO of
TiGenix. "Our state-of-the-art manufacturing site is unique in Europe as it is
100% geared towards the production of innovative cell therapy products. It
provides us with crucial manufacturing capabilities to support the anticipated
growth in demand for ChondroCelect for cartilage repair, and has sufficient
capacity for the production of our advanced stem cell therapy products."
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
Director Investor & Media Relations
hans.herklots(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect®, and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1604568]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2012 - 01:01 Uhr
Sprache: Deutsch
News-ID 1106176
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leuven
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 59 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : manufacturing license obtained for European production facility
"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
